CEO of Invisalign Braces Maker Is Confident in China
*By Conor White*
With the company's first manufacturing plant in China up and running, the chief executive of Align Technology, the maker of Invisalign orthodontics, isn't concerned about a possible trade war between the United States and China.
"By the end of the year we'll have a good, contained business in China, and be able to service our Chinese business," said Joe Hogan, the CEO of Align Technology. "So I feel great about the moves we've made there, given the talks that are going on."
Align's stock was the top performer on the S&P 500 in the last year, soaring 132 percent in 2017. The company's management has said sales could top $2 billion by 2020.
To reach that goal, the company is reaching out directly to consumers who may need its Invisalign products: clear, plastic teeth aligners taking the place of traditional metal braces.
"We have a really strong consumer business, in the sense that we advertise to consumers, and direct them toward doctors," Hogan said in an interview Tuesday with Cheddar. "So the consumer awareness part of this is a big part of this strategy also."
Consumers are increasingly aware: Invisalign shipments are up more than 30 percent year-over-year in the first quarter of this year.
For the full interview, [click here](https://cheddar.com/videos/stars-align-for-invisalign).
Smoke that filled the cabin of a Delta flight as it took off from the Atlanta airport in February was so thick the led flight attendant had trouble seeing past the first row of passengers and the pilots donned oxygen masks as a precaution.
Arjan Stephens, President of Nature's Path, discusses the company's origin, how it has evolved today and the interesting product that came from his wedding!
Small business reporter, Gene Marks, joins Cheddar to give analysis on how small businesses are tackling incoming tariffs and how it will affect the consumer.
Babylist CEO Natalie Gordon joins Cheddar to discuss how the website is helping new parents, how to make a registry and how secondhand options are available.
Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.